3,5,3'-trimethylbiphenyl-4,4'-diamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5,3'-trimethylbiphenyl-4,4'-diamine
• 英文别名: 4-(4-Amino-3-methylphenyl)-2,6-dimethylaniline
• 化学式: C₁₅H₁₈N₂
• 分子量: 226.321
• InChiKey: RUALFYOUUOQBEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,3-二甲基-2-碘苯 在 盐酸 、 palladium diacetate 、 caesium carbonate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 4.0h， 生成 3,5,3'-trimethylbiphenyl-4,4'-diamine
  参考文献：
  名称：

  Regioselective [5,5]-Sigmatropic Rearrangement Reactions of Aryl Hydrazides

  摘要：

  N,N'-Aryl hydrazides with substituents at the ortho or meta positions undergo highly regioselective [5,5]-sigmatropic rearrangement reactions to furnish benzidines in good to excellent isolated yields. The presence of single substituent at either the ortho or meta position provides sufficient bias, effectively suppressing the formation of diphenylene, the major byproduct of the conventional benzidine rearrangement reaction.

  DOI：

  10.1021/ol060451+

文献信息

• Aromatic polyimide separation membrane
  申请人：MITSUBISHI KASEI CORPORATION

  公开号：EP0407172A1

  公开（公告）日：1991-01-09

  A process is disclosed for preparing an aromatic polyimide separation membrane which comprises fluorinating an aromatic polyimide membrane with active fluorine. The aromatic polyimide separation membrane thus prepared has high selectivity and gas permeability and is therefore useful as a membrane for separation of gas mixture or liquid mixtures.

  本发明公开了一种制备芳香族聚酰亚胺分离膜的工艺，该工艺包括用活性氟氟化芳香族聚酰亚胺膜。由此制备的芳香族聚酰亚胺分离膜具有高选择性和气体渗透性，因此可用作气体混合物或液体混合物的分离膜。
• Solid phase multi-analyte assay
  申请人：Psychemedics Corporation

  公开号：EP2623987A1

  公开（公告）日：2013-08-07

  Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse, are provided. The compositions include two or more analytes associated with a solid phase, e.g., a particle or a multiwell plate. The compositions and methods also allow the simultaneous, tandem, or serial determination of the presence and/or amount of two or more analytes of interest in a sample.

  提供了用于检测一种或多种分析物（包括滥用药物等分析物）的存在和/或数量的组合物和方法。这些组合物包括与固相（如颗粒或多孔板）相关联的两种或多种分析物。这些组合物和方法还可同时、串联或连续测定样品中两种或多种相关分析物的存在和/或含量。
• Polyimide, resin film, and metal-clad laminate
  申请人：NIPPON STEEL & SUMIKIN CHEMICAL CO., LTD.

  公开号：US10077337B2

  公开（公告）日：2018-09-18

  A resin film, in which at least one of polyimide layers is a non-thermoplastic polyimide layer having a linear thermal expansion coefficient of 1×10−6 to 30×10−6 (1/K), is shown. The non-thermoplastic polyimide layer is composed of a polyimide which is produced by reacting an anhydride component containing an aromatic tetracarboxylic anhydride with a diamine component, wherein the diamine component contains both a dimer acid-type diamine produced by replacing each of two terminal carboxyl groups in a dimer acid with a primary aminomethyl or amino group and an aromatic diamine, and the dimer acid-type diamine is contained in an amount of 1 to 15 mol % relative to the whole diamine component.

  图示为一种树脂薄膜，其中至少有一层聚酰亚胺层是线性热膨胀系数为 1×10-6 至 30×10-6 (1/K) 的非热塑性聚酰亚胺层。非热塑性聚酰亚胺层由聚酰亚胺组成，该聚酰亚胺是由含有芳香族四羧酸酐的酸酐组分与二胺组分反应生成的，其中二胺组分包含二聚酸中两个末端羧基分别被伯氨基甲基或氨基取代而生成的二聚酸型二胺和芳香族二胺，二聚酸型二胺的含量相对于整个二胺组分为 1 至 15 摩尔%。
• Methods to determine KDM1A target engagement and chemoprobes useful therefor
  申请人：Oryzon Genomics S.A.

  公开号：US11034991B2

  公开（公告）日：2021-06-15

  The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

  本发明涉及确定 KDM1A 靶点接合的方法以及对其有用的化学试剂。特别是，本发明涉及携带标记或标签的非肽 KDM1A 化学试剂，可用于评估细胞和组织中的 KDM1A 靶向接合。这些化学试剂还可用于鉴定 KDM1A 的相互作用因子和分析 KDM1A 的表达水平。
• Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
  申请人：Akston Biosciences Corporation

  公开号：US11213581B2

  公开（公告）日：2022-01-04

  The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

  本公开提供了重组制造的融合蛋白，其包含与人Fc片段相连的SARS-CoV-2受体结合域（SARS-CoV-2-RBD）片段或其类似物，用于2019年新型冠状病毒（COVID-19）。本发明的实施方案包括将融合蛋白注射给从 COVID-19 中康复的患者，作为加强免疫；注射给抗体幼稚的患者，使其产生针对 SARS-CoV-2 病毒的抗体，从而使患者成为康复血浆捐献者；注射给已被 SARS-CoV-2 病毒感染并感染 COVID-19 的患者，以限制感染范围并改善病情；以及作为预防性 COVID-19 疫苗。除了使用和制备方法外，还提供了示例性 Fc 融合蛋白和示例性 Fc 融合蛋白的药物制剂。